302 related articles for article (PubMed ID: 37347261)
1. Identification a unique disulfidptosis classification regarding prognosis and immune landscapes in thyroid carcinoma and providing therapeutic strategies.
Feng Z; Zhao Q; Ding Y; Xu Y; Sun X; Chen Q; Zhang Y; Miao J; Zhu J
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11157-11170. PubMed ID: 37347261
[TBL] [Abstract][Full Text] [Related]
2. Identification an innovative classification and nomogram for predicting the prognosis of thyroid carcinoma patients and providing therapeutic schedules.
Feng Z; Zhao Q; Ding Y; Xu Y; Sun X; Chen Q; Zhang Y; Miao J; Zhu J
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14817-14831. PubMed ID: 37596371
[TBL] [Abstract][Full Text] [Related]
3. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T
BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405
[TBL] [Abstract][Full Text] [Related]
4. Identification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer.
Liang J; Wang X; Yang J; Sun P; Sun J; Cheng S; Liu J; Ren Z; Ren M
Front Immunol; 2023; 14():1198826. PubMed ID: 38035071
[TBL] [Abstract][Full Text] [Related]
5. A novel prognostic signature and immune microenvironment characteristics associated with disulfidptosis in papillary thyroid carcinoma based on single-cell RNA sequencing.
Liao Z; Cheng Y; Zhang H; Jin X; Sun H; Wang Y; Yan J
Front Cell Dev Biol; 2023; 11():1308352. PubMed ID: 38033866
[No Abstract] [Full Text] [Related]
6. Prognosis and therapy in thyroid cancer by gene signatures related to natural killer cells.
Jin Z; Han Y; Zhang J; Liu Z; Li R; Liu Z
J Gene Med; 2024 Jan; 26(1):e3657. PubMed ID: 38282150
[TBL] [Abstract][Full Text] [Related]
7. Preliminary findings on the development of a predictive model for BLCA based on disulfidptosis-associated IncRNAs signature.
Tang C; Fan Y; Zhu S
BMC Urol; 2024 Mar; 24(1):69. PubMed ID: 38532369
[TBL] [Abstract][Full Text] [Related]
8. Identification of m6A-associated LncRNAs as predict factors for the immune infiltration and prognosis of thyroid cancer.
Su Y; Xu B; Li J; Shen Q; Lei Z; Ma M; Zhang F; Hu T
Ann Med; 2023 Dec; 55(1):1298-1316. PubMed ID: 36974635
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
[TBL] [Abstract][Full Text] [Related]
10. Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile.
Wang T; Guo K; Zhang D; Wang H; Yin J; Cui H; Wu W
Int Immunopharmacol; 2023 Jul; 120():110368. PubMed ID: 37247499
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the role of disulfidptosis-related LncRNAs in colon cancer: a prognostic indicator for immunotherapy response, chemotherapy sensitivity, and insights into cell death mechanisms.
Chi H; Huang J; Yan Y; Jiang C; Zhang S; Chen H; Jiang L; Zhang J; Zhang Q; Yang G; Tian G
Front Mol Biosci; 2023; 10():1254232. PubMed ID: 37916187
[No Abstract] [Full Text] [Related]
12. Construction of a novel disulfidptosis-related signature for improving outcomes in hepatocellular carcinoma: Observational study.
Chen X; Liang Q; Zhou Y
Medicine (Baltimore); 2023 Oct; 102(40):e35423. PubMed ID: 37800779
[TBL] [Abstract][Full Text] [Related]
13. Identification of disulfidptosis related subtypes, characterization of tumor microenvironment infiltration, and development of DRG prognostic prediction model in RCC, in which
Xu K; Zhang Y; Yan Z; Wang Y; Li Y; Qiu Q; Du Y; Chen Z; Liu X
Front Immunol; 2023; 14():1205250. PubMed ID: 37426643
[TBL] [Abstract][Full Text] [Related]
14. Estrogen-related genes for thyroid cancer prognosis, immune infiltration, staging, and drug sensitivity.
Zhang L; Zhou M; Gao X; Xie Y; Xiao J; Liu T; Zeng X
BMC Cancer; 2023 Oct; 23(1):1048. PubMed ID: 37907864
[TBL] [Abstract][Full Text] [Related]
15. Typing and modeling of hepatocellular carcinoma based on disulfidptosis-related amino acid metabolism genes for predicting prognosis and guiding individualized treatment.
Chen X; Wang Z; Wu Y; Lan Y; Li Y
Front Oncol; 2023; 13():1204335. PubMed ID: 37637055
[TBL] [Abstract][Full Text] [Related]
16. Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration.
Wei J; Wang J; Chen X; Zhang L; Peng M
PeerJ; 2024; 12():e16819. PubMed ID: 38317842
[TBL] [Abstract][Full Text] [Related]
17. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
Xiong Y; Kong X; Mei H; Wang J; Zhou S
Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783
[TBL] [Abstract][Full Text] [Related]
18. Impact of disulfidptosis-associated clusters on breast cancer survival rates and guiding personalized treatment.
Chen X; Hu G; Yu Q
Front Endocrinol (Lausanne); 2023; 14():1256132. PubMed ID: 38116315
[TBL] [Abstract][Full Text] [Related]
19. Signature Construction and Disulfidptosis-Related Molecular Cluster Identification for Better Prediction of Prognosis in Glioma.
Zhuang Y; Chen J; Mai Z; Huang W; Zhong W
J Mol Neurosci; 2024 Apr; 74(2):38. PubMed ID: 38573391
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
